levofloxacin has been researched along with posaconazole in 4 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (posaconazole) | Trials (posaconazole) | Recent Studies (post-2010) (posaconazole) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,575 | 103 | 1,014 |
| Protein | Taxonomy | levofloxacin (IC50) | posaconazole (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.1 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 0.921 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2458 | |
| Aromatase | Homo sapiens (human) | 8.4 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 7.2 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.31 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.021 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.464 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frauenfelder, T; Gerber, B; Köppel, J; Manz, MG; Nair, G; Nguyen-Kim, TD; Paul, M; Schanz, U | 1 |
| Bateman, AC; Clarridge, J; Garvin, K; Greenbaum, A; Grim, J; Liu, AW | 1 |
1 review(s) available for levofloxacin and posaconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for levofloxacin and posaconazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Agents; Bacteremia; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Mycoses; Retrospective Studies; Survival Rate; Triazoles | 2014 |
Cutaneous phaeohyphomycosis in a hematopoietic stem cell transplant patient caused by Alternaria rosae: First case report.
Topics: Acute Kidney Injury; Acyclovir; Aged; Alternaria; Alternariosis; Antibiotic Prophylaxis; Antifungal Agents; Drug Therapy, Combination; Fatal Outcome; Graft vs Host Disease; Hand; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Levofloxacin; Magnetic Resonance Imaging; Male; Microbial Sensitivity Tests; Paranasal Sinuses; Phaeohyphomycosis; Pneumonia; Prednisone; Primary Myelofibrosis; Respiratory Insufficiency; Spores, Fungal; Transplantation, Homologous; Triazoles; Voriconazole | 2017 |